NCT03441789View on ClinicalTrials.gov

Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

October 1, 2018

Study Completion Date

October 22, 2018

Conditions
Plaque Psoriasis
Interventions
DRUG

Enstilar

Enstilar foam applied to affected areas daily

DRUG

Vehicle

vehicle foam applied to affected areas once daily

DRUG

Otezla

Otezla 30mg

Trial Locations (4)

20850

Lawrence J. Green, MD LLC, Rockville

29414

Dermatology & Laser Center of Charleston, Charleston

40217

Skin Sciences, PLLC, Louisville

95819

Center for Dermatology and Laser Surgery, Sacramento

All Listed Sponsors
lead

L.H. Kircik, M.D.

OTHER

NCT03441789 - Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis | Biotech Hunter | Biotech Hunter